Skip to main content
Top
Published in: Diabetologia 10/2012

01-10-2012 | Article

TCF7L2 rs7903146 impairs islet function and morphology in non-diabetic individuals

Authors: O. Le Bacquer, J. Kerr-Conte, S. Gargani, N. Delalleau, M. Huyvaert, V. Gmyr, P. Froguel, B. Neve, F. Pattou

Published in: Diabetologia | Issue 10/2012

Login to get access

Abstract

Aims/hypothesis

Transcription factor 7-like 2 (TCF7L2) is a Wnt-signalling-associated transcription factor. Genetic studies have clearly demonstrated that DNA polymorphisms within TCF7L2 confer the strongest known association with increased risk of type 2 diabetes. However, the impact of the TCF7L2 type-2-diabetes-associated rs7903146 T allele on biological function and morphology of human pancreatic islets is unknown.

Methods

Paraffin sections of pancreases from 187 brain-deceased donors (HbA1c <6.5% [48 mmol/mol]) were used to genotype the TCF7L2 variant rs7903146 and evaluate its impact on islet morphology and alpha and beta cell subpopulations following immunostaining for glucagon and C-peptide. Following islet isolation, we investigated the correlation between TCF7L2 genotype and in vitro islet functional variables from our in-house pancreatic database.

Results

TCF7L2 rs7903146 (T/T) was associated with reduced basal and glucose-stimulated insulin secretion in isolated human islets, and reduced islet density in whole pancreas. Morphological analysis demonstrated islet size was increased in T/T carriers. Furthermore, rs7903146 was associated with an increased glucagon/C-peptide ratio, especially in bigger islets.

Conclusion/interpretation

The TCF7L2 variant rs7903146 risk allele is associated with impaired insulin secretion, reduction of total islet number and quantitative as well as qualitative morphological changes in human islets. Understanding how the TCF7L2 genotype modulates its activity and how TCF7L2 impacts the islet morphology may aid the design of new therapeutic approaches for the treatment of type 2 diabetes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Schafer SA, Machicao F, Fritsche A, Haring HU, Kantartzis K (2011) New type 2 diabetes risk genes provide new insights in insulin secretion mechanisms. Diabetes Res Clin Pract 93(Suppl 1):S9–S24PubMedCrossRef Schafer SA, Machicao F, Fritsche A, Haring HU, Kantartzis K (2011) New type 2 diabetes risk genes provide new insights in insulin secretion mechanisms. Diabetes Res Clin Pract 93(Suppl 1):S9–S24PubMedCrossRef
2.
go back to reference Le Bacquer O, Shu L, Marchand M et al (2011) TCF7L2 splice variants have distinct effects on beta cell turnover and function. Hum Mol Genet 20:1906–1915PubMedCrossRef Le Bacquer O, Shu L, Marchand M et al (2011) TCF7L2 splice variants have distinct effects on beta cell turnover and function. Hum Mol Genet 20:1906–1915PubMedCrossRef
3.
go back to reference Shu L, Matveyenko AV, Kerr-Conte J, Cho JH, McIntosh CH, Maedler K (2009) Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta cell function. Hum Mol Genet 18:2388–2399PubMedCrossRef Shu L, Matveyenko AV, Kerr-Conte J, Cho JH, McIntosh CH, Maedler K (2009) Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta cell function. Hum Mol Genet 18:2388–2399PubMedCrossRef
4.
go back to reference Rosengren AH, Braun M, Mahdi T et al (2012) Reduced insulin exocytosis in human pancreatic beta cells with gene variants linked to type 2 diabetes. Diabetes 61:1726–1733PubMedCrossRef Rosengren AH, Braun M, Mahdi T et al (2012) Reduced insulin exocytosis in human pancreatic beta cells with gene variants linked to type 2 diabetes. Diabetes 61:1726–1733PubMedCrossRef
5.
go back to reference Vantyghem MC, Kerr-Conte J, Arnalsteen L et al (2009) Primary graft function, metabolic control, and graft survival after islet transplantation. Diabetes Care 32:1473–1478PubMedCrossRef Vantyghem MC, Kerr-Conte J, Arnalsteen L et al (2009) Primary graft function, metabolic control, and graft survival after islet transplantation. Diabetes Care 32:1473–1478PubMedCrossRef
6.
go back to reference Lyssenko V, Lupi R, Marchetti P et al (2007) Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 117:2155–2163PubMedCrossRef Lyssenko V, Lupi R, Marchetti P et al (2007) Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 117:2155–2163PubMedCrossRef
7.
go back to reference Takeda Y, Fujita Y, Honjo J et al (2012) Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice. Diabetologia 55:404–412PubMedCrossRef Takeda Y, Fujita Y, Honjo J et al (2012) Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice. Diabetologia 55:404–412PubMedCrossRef
8.
go back to reference Yoon KH, Ko SH, Cho JH et al (2003) Selective beta cell loss and alpha cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 88:2300–2308PubMedCrossRef Yoon KH, Ko SH, Cho JH et al (2003) Selective beta cell loss and alpha cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 88:2300–2308PubMedCrossRef
9.
go back to reference Kirkpatrick CL, Marchetti P, Purrello F et al (2010) Type 2 diabetes susceptibility gene expression in normal or diabetic sorted human alpha and beta cells: correlations with age or BMI of islet donors. PLoS One 5:e11053PubMedCrossRef Kirkpatrick CL, Marchetti P, Purrello F et al (2010) Type 2 diabetes susceptibility gene expression in normal or diabetic sorted human alpha and beta cells: correlations with age or BMI of islet donors. PLoS One 5:e11053PubMedCrossRef
10.
go back to reference Ackermann AM, Gannon M (2007) Molecular regulation of pancreatic beta cell mass development, maintenance, and expansion. J Mol Endocrinol 38:193–206PubMedCrossRef Ackermann AM, Gannon M (2007) Molecular regulation of pancreatic beta cell mass development, maintenance, and expansion. J Mol Endocrinol 38:193–206PubMedCrossRef
11.
go back to reference Figeac F, Uzan B, Faro M, Chelali N, Portha B, Movassat J (2010) Neonatal growth and regeneration of beta cells are regulated by the Wnt/beta-catenin signaling in normal and diabetic rats. Am J Physiol Endocrinol Metab 298:E245–E256PubMedCrossRef Figeac F, Uzan B, Faro M, Chelali N, Portha B, Movassat J (2010) Neonatal growth and regeneration of beta cells are regulated by the Wnt/beta-catenin signaling in normal and diabetic rats. Am J Physiol Endocrinol Metab 298:E245–E256PubMedCrossRef
12.
go back to reference Schafer SA, Tschritter O, Machicao F et al (2007) Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 50:2443–2450PubMedCrossRef Schafer SA, Tschritter O, Machicao F et al (2007) Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 50:2443–2450PubMedCrossRef
Metadata
Title
TCF7L2 rs7903146 impairs islet function and morphology in non-diabetic individuals
Authors
O. Le Bacquer
J. Kerr-Conte
S. Gargani
N. Delalleau
M. Huyvaert
V. Gmyr
P. Froguel
B. Neve
F. Pattou
Publication date
01-10-2012
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 10/2012
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-012-2660-8

Other articles of this Issue 10/2012

Diabetologia 10/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.